Zymeworks Inc. (ZYME)
USD 12.34
(-1.91%)
USD 12.34
(-1.91%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -66.97 Million USD | -132.87% |
| 2022 | 203.77 Million USD | 217.89% |
| 2021 | -172.85 Million CAD | -31.01% |
| 2020 | -131.94 Million USD | -50.7% |
| 2019 | -87.55 Million USD | -2140.9% |
| 2018 | -3.9 Million USD | -136.8% |
| 2017 | 10.61 Million USD | 143.26% |
| 2016 | -24.54 Million USD | -66.47% |
| 2015 | -14.74 Million USD | -67.48% |
| 2014 | -8.8 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 16.71 Million USD | 173.59% |
| 2024 Q1 | -22.71 Million USD | -173.67% |
| 2024 Q3 | 13.33 Million USD | -20.2% |
| 2023 Q3 | -16.43 Million USD | 49.28% |
| 2023 Q1 | -9.83 Million USD | -102.82% |
| 2023 Q2 | -32.4 Million USD | -229.5% |
| 2023 FY | -66.97 Million USD | -132.87% |
| 2023 Q4 | -8.29 Million USD | 49.51% |
| 2022 Q2 | -50.58 Million USD | 16.53% |
| 2022 FY | 203.77 Million USD | 217.89% |
| 2022 Q4 | 349.04 Million USD | 1112.72% |
| 2022 Q3 | -34.46 Million USD | 31.86% |
| 2022 Q1 | -60.59 Million USD | -74.06% |
| 2021 Q4 | -34.81 Million CAD | 23.48% |
| 2021 Q2 | -48.94 Million USD | -12.15% |
| 2021 FY | -172.85 Million CAD | -31.01% |
| 2021 Q1 | -43.63 Million USD | -81.16% |
| 2021 Q3 | -45.49 Million USD | 7.03% |
| 2020 Q2 | -26.85 Million USD | 6.33% |
| 2020 Q1 | -28.67 Million USD | 34.1% |
| 2020 Q4 | -24.08 Million USD | 53.46% |
| 2020 FY | -131.94 Million USD | -50.7% |
| 2020 Q3 | -51.75 Million USD | -92.71% |
| 2019 Q1 | -5.55 Million USD | -137.89% |
| 2019 FY | -87.55 Million USD | -2140.9% |
| 2019 Q4 | -43.51 Million USD | -103.41% |
| 2019 Q3 | -21.39 Million USD | -34.51% |
| 2019 Q2 | -15.9 Million USD | -186.54% |
| 2018 Q3 | -12.14 Million USD | -283.07% |
| 2018 Q4 | 14.64 Million USD | 220.64% |
| 2018 FY | -3.9 Million USD | -136.8% |
| 2018 Q1 | -13.04 Million USD | -134.28% |
| 2018 Q2 | 6.63 Million USD | 150.84% |
| 2017 Q1 | -8.61 Million USD | -58.83% |
| 2017 Q2 | -6.94 Million USD | 19.31% |
| 2017 Q3 | -11.4 Million USD | -64.19% |
| 2017 Q4 | 38.05 Million USD | 433.61% |
| 2017 FY | 10.61 Million USD | 143.26% |
| 2016 Q3 | -7.58 Million USD | -95.54% |
| 2016 Q2 | -3.88 Million USD | 49.31% |
| 2016 Q1 | -7.65 Million USD | -16.91% |
| 2016 FY | -24.54 Million USD | -66.47% |
| 2016 Q4 | -5.42 Million USD | 28.55% |
| 2015 FY | -14.74 Million USD | -67.48% |
| 2015 Q4 | -6.54 Million USD | 0.0% |
| 2014 FY | -8.8 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ADC Therapeutics SA | 67.02 Million USD | 199.922% |
| Alto Neuroscience, Inc. | -373 Thousand USD | -17856.3% |
| Annovis Bio, Inc. | - USD | Infinity% |
| Biohaven Pharmaceutical Holding Company Ltd. | -3.36 Million USD | -1888.038% |
| Ginkgo Bioworks Holdings, Inc. | 197.45 Million USD | 133.921% |
| Nuvation Bio Inc. | -222 Thousand USD | -30069.82% |
| Nuvation Bio Inc. | -222 Thousand USD | -30069.82% |
| Arcus Biosciences, Inc. | -223 Million USD | 69.965% |
| Theriva Biologics, Inc. | -135 Thousand USD | -49512.593% |